| According to a new market research report, | | | | estimated $11.5 billion by 2014. This market has a high |
| ‘Global biosimilars Market (2009 - 2014)', published | | | | CAGR of 87.9% from 2009 to 2014 mainly because |
| by MarketsandMarkets ( the global biosimilars market | | | | most of the branded blockbuster biopharmaceutical |
| is expected to be worth US$19.4 billion by 2014, | | | | drugs such as interferon, human growth hormone |
| recording a CAGR of 89.1% from 2009 to 2014. The | | | | (Somatropin), insulin and G-CSF, belong to this class |
| increasing demand from patients, insurers, and | | | | and have wide range of applications. |
| government agencies to reduce the costs of | | | | Scope of the Report |
| blockbuster biopharmaceuticals has created numerous | | | | This report aims to identify and analyze biosimilars |
| opportunities in the global biosimilars market. | | | | market on the basis of products, services, |
| Browse more than 60 market data tables and | | | | technology, and applications. |
| in-depth TOC on biosimilars market. | | | | - Biosimilars product market: Peptides, recombinant |
| Early buyers will receive 10% customization of | | | | glycosylated proteins, recombinant non-glycosylated |
| reports. | | | | proteins, and others |
| Currently, the biosimilars market is highly fragmented | | | | Biosimilars service market: Contract research and |
| and its huge opportunities are attracting new players. | | | | manufacturing services, clinical trials services |
| Favourable regulatory developments in the biosimilars | | | | - Biosimilars applications market: Oncology, infectious |
| sector are expected to increase the market share | | | | diseases, chronic and autoimmune diseases, and other |
| and profit margins while reducing medical expenditure. | | | | diseases |
| Asia's early commercialization and high absorption rate | | | | - Biosimilars technology market: Recombinant DNA |
| of biosimilars products made it the dominant market | | | | technology, monoclonal antibodies technologies, |
| in 2008 with 34.1% share of the global biosimilars | | | | protein sequencing, bioassay, chromatography, |
| product market. The American market (including | | | | nuclear magnetic resonance, and mass spectrometry |
| North America and Latin America) is expected to | | | | Each section will provide market data, market drivers, |
| account for nearly 35.3% of the total revenues in | | | | trends and opportunities, top-selling products, key |
| 2014. The European market is also gaining momentum | | | | players, and competitive outlook. This report will also |
| after the approval of its first biosimilars Omnitrope in | | | | provide more than 60 market tables for various |
| 2006. | | | | geographic regions covering the sub-segments and |
| Recombinant non-glycosylated proteins form the | | | | micro-markets. In addition, the report also provides |
| largest segment in biosimilars market, with an | | | | 40 company profiles for each of its sub-segments. |